Can-Fite BioPharma Ltd. (NYSE:CANF) reported extended survival trends in a key late-stage cancer trial alongside a $4 million warrant exercise agreement to fund ongoing clinical operations.
• Can Fite Biopharma stock is at significant support. What is going on with CANF?
The clinical-stage biotechnology company observed longer-than-expected blinded overall survival in its ongoing pivotal Phase 3 trial evaluating Namodenoson for advanced hepatocellular carcinoma (HCC).
The study focuses on HCC patients with Child-Pugh B7 cirrhosis, utilizing overall survival as its primary efficacy endpoint.
Because the observed data reflect a pooled, blinded population across both treatment arms, the company cannot draw conclusions regarding drug efficacy or comparative differences yet.
#biopharma #clinical
• Can Fite Biopharma stock is at significant support. What is going on with CANF?
The clinical-stage biotechnology company observed longer-than-expected blinded overall survival in its ongoing pivotal Phase 3 trial evaluating Namodenoson for advanced hepatocellular carcinoma (HCC).
The study focuses on HCC patients with Child-Pugh B7 cirrhosis, utilizing overall survival as its primary efficacy endpoint.
Because the observed data reflect a pooled, blinded population across both treatment arms, the company cannot draw conclusions regarding drug efficacy or comparative differences yet.
#biopharma #clinical
2 months ago
